Summary of Key Points Core Viewpoint - The company announced that several executives, including the director Dai Ya and vice general managers Zhang Shengquan and Lou Yanjun, along with the secretary Hu Kangkang, have collectively reduced their holdings by 102,900 shares, representing 0.0675% of the total share capital between December 26 and December 31, 2025 [1] Group 1: Share Reduction Details - Dai Ya reduced his holdings by 24,420 shares [1] - Zhang Shengquan and Lou Yanjun each reduced their holdings by 25,530 shares [1] - Hu Kangkang also reduced his holdings by 24,420 shares [1] - Financial director Pan Aijuan reduced her holdings by 3,000 shares at an average price of 22.06 yuan per share [1] - Pan Aijuan has terminated the remaining plan to reduce 21,420 shares [1]
海森药业：多名高管已合计减持0.0675%股份 减持计划提前终止